On June 2, 2025, Rapport Therapeutics, Inc. reported that its Phase 2a trial for RAP-219 in refractory focal epilepsy is fully enrolled, with topline results expected in September 2025, and shared new data from previous Phase 1 trials showing good tolerability with no serious adverse events among 64 participants.